SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca signed an exclusive global license agreement for Zegfrovy…

ASTRAZENECA PLC · 6-K filed Jul 14, 2026 at 06:37 ET

At the news

BULLISHIMPACT 7/10

6-K filed Jul 14, 2026 at 06:37 ET

AstraZeneca signed an exclusive global license agreement for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for non-small cell lung cancer with exon 20 insertion mutations. AstraZeneca pays Dizal Pharmaceutical an upfront $600 million plus up to $900 million in milestones, plus tiered royalties, adding a complementary approved asset to its lung cancer portfolio with positive Phase III data already filed for first-line use.

  • AstraZeneca licensed worldwide rights to Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor for NSCLC with EGFR exon 20 insertion mutations.
  • Upfront payment of $600 million to Dizal, with up to $900 million in development, regulatory, and sales milestones, plus tiered royalties on global sales.
  • Zegfrovy is already approved in the US and China for second-line treatment after platinum-based chemotherapy.
  • Positive WU-KONG28 Phase III data presented at ASCO 2026 and published in NEJM; sNDA for first-line use submitted to FDA and CDE.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access